Role of clinical pharmacogenetics & Histopathological to identification of Treated Thyroid Cancer

Abstract

Lately, an increased incidence of thyroid cancer has been reported around the world. In Libya there are a few studies which have investigated thyroid cancer, so we conduct this study by nanotechnology technique in clinical pharmacology through pharmacogenetics technical the best scientific way by in vivo or in-vitro   identification how Xenobiotic-metabolizing enzymes are widely polymorphic and confer interindividual variation in the ability to detoxify carcinogens or to activate pro-carcinogens. A common polymorphism of cytochrome P450 2D6 (CYP2D6) results in lack of enzyme activity and has been associated with an altered susceptibility to several cancers

   to explore the incidence and the clinical pathological presentations of thyroid cancer among patients diagnosed in Histopathology department at Tripoli Medical center. from 210 patients diagnosed with thyroid cancer during the period from January 2002 till December 2012 have been analyzed. There were 176 Female and 34 Male patients. The histopathological pattern of the disease was 61.43%   papillary cancer, 13.33% follicular, 7.14 % medullary, 5.24% Hurtle cell carcinoma,4.29 % lymphoid tumor, 2.3% anaplastic, and the other histological types were 4.76%. We concluded that Thyroid cancer is more common in female compared to male. The most common histopathological pattern was for Papillary carcinoma (61.43%). We further need multicenter studiesof thyroid malignancy to investigate and to know the national pattern and trend of thyroid cancer in.